Free tool
FAERS Monitor: Ensacove
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218171 or its brand name (Ensacove, Ensartinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
45
Serious
34
76% of reports
Hospitalization
16
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash9
- pruritus7
- constipation6
- drug ineffective5
- fatigue5
- death4
- disease progression4
- oedema4
- adverse event3
- product use issue3
- rash pruritic3
- alanine aminotransferase increased2
- aspartate aminotransferase increased2
- atrial fibrillation2
- confusional state2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| oedemaSignal | 4 | 34.5 | 13.5 | 99 |
| rash pruriticSignal | 3 | 25.9 | 8.7 | 49 |
| aspartate aminotransferase increased | 2 | 17.6 | 4.5 | 17 |
| disease progressionSignal | 4 | 15.8 | 6.2 | 42 |
| alanine aminotransferase increased | 2 | 15.2 | 3.9 | 14 |
| adverse eventSignal | 3 | 15.2 | 5.1 | 27 |
| constipationSignal | 6 | 12.9 | 6.1 | 55 |
| rashSignal | 9 | 9.7 | 5.4 | 63 |
| atrial fibrillation | 2 | 9.6 | 2.5 | 8 |
| pruritusSignal | 7 | 8.5 | 4.3 | 40 |
| product use issueSignal | 3 | 7.5 | 2.5 | 11 |
| confusional state | 2 | 5.8 | 1.5 | 4 |
| fatigueSignal | 5 | 3.0 | 1.3 | 5 |
| death | 4 | 2.2 | 0.9 | 2 |
| drug ineffective | 5 | 1.8 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.